Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R. Kataoka, Satoshi Morita, Masakazu Toi

Open source

DOI: 10.1007/s10549-024-07333-7
Published: 2024-05-20
Container: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-024-07333-7,
  title = {Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)},
  author = {Toshimi Takano and Norikazu Masuda and Mitsuya Ito and Kenichi Inoue and Yuko Tanabe and Kousuke Kawaguchi and Hiroyuki Yasojima and Hiroko Bando and Rikiya Nakamura and Takashi Yamanaka and Kazushige Ishida and Tomoyuki Aruga and Yasuhiro Yanagita and Eriko Tokunaga and Kenjiro Aogi and Shinji Ohno and Hiroi Kasai and Tatsuki R. Kataoka and Satoshi Morita and Masakazu Toi},
  year = {2024},
  journal = {Breast Cancer Research and Treatment},
  doi = {10.1007/s10549-024-07333-7},
  url = {https://doi.org/10.1007/s10549-024-07333-7}
}

RIS

TY  - JOUR
TI  - Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
AU  - Toshimi Takano
AU  - Norikazu Masuda
AU  - Mitsuya Ito
AU  - Kenichi Inoue
AU  - Yuko Tanabe
AU  - Kousuke Kawaguchi
AU  - Hiroyuki Yasojima
AU  - Hiroko Bando
AU  - Rikiya Nakamura
AU  - Takashi Yamanaka
AU  - Kazushige Ishida
AU  - Tomoyuki Aruga
AU  - Yasuhiro Yanagita
AU  - Eriko Tokunaga
AU  - Kenjiro Aogi
AU  - Shinji Ohno
AU  - Hiroi Kasai
AU  - Tatsuki R. Kataoka
AU  - Satoshi Morita
AU  - Masakazu Toi
PY  - 2024
JO  - Breast Cancer Research and Treatment
DO  - 10.1007/s10549-024-07333-7
UR  - https://doi.org/10.1007/s10549-024-07333-7
ER  -

APA

Takano, T., Masuda, N., Ito, M., Inoue, K., Tanabe, Y., Kawaguchi, K., Yasojima, H., Bando, H., Nakamura, R., Yamanaka, T., Ishida, K., Aruga, T., Yanagita, Y., Tokunaga, E., Aogi, K., Ohno, S., Kasai, H., Kataoka, T. R., Morita, S., & Toi, M. (2024). Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07333-7

Source records

crossref · retrieved 2026-09-27T10:11:44.792Z